* Histologically or cytologically confirmed and adequately resected non-metastatic primary invasive breast cancer;
* Subjects must have positive lymph nodes or tumors \> 2 cm;
* The interval between radical surgery and the first dose ≤ 60 days;
Eastern Cooperative Oncology Group (ECOG) performance score 0-1;
have appropriate organ function, meet the following criteria: (1) have appropriate bone marrow function: Hb ≥ 100 g/L (no ESA and blood transfusion within 14 days before the first dose); absolute neutrophil count (ANC) ≥ 2 × 10\^9/L (no G-CSF within 14 days before the first dose); platelet count ≥ 100 × 10\^9/L (no rhTPO/rhIL-11 and platelet transfusion within 14 days before the first dose); (2) appropriate liver and kidney function: alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN), aspartate aminotransferase (AST) ≤ 2.5 × ULN, total bilirubin (TBIL) ≤ 1.5 × ULN, serum creatinine ≤ 1.5 × ULN, endogenous creatinine clearance \> 50 ml/min (Cockcroft-Gault formula); (3) appropriate cardiac function: left ventricular ejection fraction (LVEF) ≥ 55%;
Non-hematologic toxicities from prior surgical procedures recovered to ≤ Grade 1 or baseline (except alopecia);
Females of childbearing potential agree to practice reliable contraception during the clinical trial and have a negative serum or urine pregnancy test within 7 days prior to dosing;
Voluntarily join this study and sign informed consent, have good compliance and are willing to cooperate with follow-up.
You may not be if
Prior neoadjuvant therapy (including chemotherapy, targeted therapy, immunotherapy, or radiotherapy);
History of other malignancy within 5 years prior to first dose, except basal cell carcinoma and cervical carcinoma in situ;
Any T4 or N2 or known N3 or M1 breast cancer;
Subjects who cannot receive or tolerate postoperative chemotherapy for various reasons;
Heart disease ineligible for epirubicin, docetaxel, trastuzumab/pertuzumab:
* Any documented history of myocardial infarction, congestive heart failure
